CYCN Stock Profile: Cyclerion Therapeutics, Inc.

Key Finding: Cyclerion Therapeutics (CYCN), a micro-cap biotech, has pivoted to neuropsychiatric drug development and announced a major all-stock merger with Korsana Biosciences in April 2026, triggering extreme stock volatility with a 300%+ surge followed by stabilization around $3.40–$3.50 as of early July 2026.

Company Overview

Fact: Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, MA, focused on developing therapeutics for neuropsychiatric diseases, with its foundational candidate CYC-126 targeting treatment-resistant depression (TRD).

Fact: It originally specialized in soluble guanylate cyclase (sGC) stimulators modulating the NO-cGMP pathway for serious and orphan diseases before strategic shifts.

Interpretation: The company appears to be repositioning from broad sGC pharmacology to a more targeted neuropsychiatry focus amid pipeline prioritization.

Company History

Fact: Founded September 6, 2018; spun off as an independent public company from Ironwood Pharmaceuticals on April 1, 2019, via tax-free distribution, trading under CYCN on Nasdaq.

Fact: Key milestones include 2021 out-licensing of praliciguat, 2023 sale of zagociguat and CY3018 to Tisento, 2024 non-binding option for olinciguat, September 2025 relaunch as neuropsychiatric-focused entity via MIT licensing, and April 1, 2026 merger announcement with Korsana Biosciences.

Data Limitation/Assumption: Historical details primarily from company disclosures and press releases up to July 2026; post-merger entity (Korsana Biosciences) status and completion remain pending regulatory/shareholder approval as of latest data.

Recent News (2025–2026)

Interpretation: News flow indicates aggressive pipeline and corporate restructuring to attract capital and advance clinical programs in high-unmet-need areas like TRD and potentially Alzheimer's post-merger.

Stock Performance

Fact: As of July 8, 2026 close: ~$3.475 (down 0.14% that day); 52-week range $1.03–$8.48; market cap ~$15M; shares outstanding ~4.33M; average daily volume low (~17K–27K shares).

Fact: Strong YTD return (~170%+) driven primarily by merger announcement; 1-year return modest (~10–13%); long-term (5-year) deeply negative (>-95%) reflecting prior clinical setbacks and dilution.

MetricValue (as of ~July 8, 2026)Notes
Price$3.43 – $3.48Volatile; post-merger stabilization
52-Week High$8.48Post-April 2026 surge
52-Week Low$1.03Pre-merger levels
Market Cap~$15MMicro-cap classification
P/E RatioN/A (negative EPS ~-$1.37)Pre-revenue clinical stage
YTD Return~170–175%Merger catalyst

Interpretation: Extreme volatility typical of low-float biotech penny stocks reacting to binary events like mergers and regulatory feedback; limited liquidity increases risk.

Links for More Information

Data Limitations & Assumptions: All information current as of July 10, 2026 (tool crawl dates ~July 8–9, 2026). Stock prices, volumes, and news are time-sensitive and subject to rapid change. Merger completion, clinical trial outcomes, and post-merger performance are uncertain. No forward-looking financial projections provided; past performance (e.g., long-term declines) does not predict future results. Sources primarily company releases and financial portals; verify with primary filings (e.g., SEC) for accuracy.

Sources: Aggregated from web search results including Yahoo Finance, company IR, Nasdaq, Morningstar, and GlobeNewswire (2025–2026). Inline facts traceable to these.